HC Wainwright Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective increased by analysts at HC Wainwright from $130.00 to $158.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 40.44% from the stock’s current price.

Several other brokerages also recently issued reports on DNTH. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush raised their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $122.64.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $112.50 on Thursday. The company has a 50-day moving average of $94.02 and a two-hundred day moving average of $79.98. The stock has a market cap of $6.15 billion, a price-to-earnings ratio of -27.11 and a beta of 1.22. Dianthus Therapeutics has a one year low of $18.08 and a one year high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 25.73%. Analysts anticipate that Dianthus Therapeutics will post -3.82 earnings per share for the current year.

Insider Buying and Selling at Dianthus Therapeutics

In other news, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $362,480. The trade was a 86.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Ryan Savitz sold 31,249 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president directly owned 31,249 shares in the company, valued at $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 87,779 shares of company stock valued at $7,985,235 in the last quarter. Company insiders own 3.02% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DNTH. First Horizon Corp acquired a new position in Dianthus Therapeutics in the first quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in Dianthus Therapeutics in the fourth quarter valued at approximately $40,000. Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics in the second quarter worth approximately $27,000. Russell Investments Group Ltd. bought a new stake in Dianthus Therapeutics in the third quarter worth approximately $64,000. Finally, ABS Direct Equity Fund LLC acquired a new position in shares of Dianthus Therapeutics during the 1st quarter worth $179,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.